Fig. 1
Overexpression of GOLPH3L correlates with ovarian cancer progression and poor prognosis. a-b Expression profiling of mRNAs showing that GOLPH3L is upregulated in ovarian cancer tissues (T) compared to normal tissues. c Kaplan-Meier analysis of overall (left panel) or disease-free (right panel) survival curves from TCGA dataset for ovarian cancer patients with low GOLPH3L expression or high GOLPH3L expression. *P < 0.05. d Western blotting analysis of GOLPH3L expression in one immortalized epithelial cell line (IOSE80) and 9 cultured ovarian cancer cell lines. e Western blotting analysis of GOLPH3L expression in eight human ovarian cancer tissues (T) and two non-tumor tissues (ANT), α-Tubulin was used as a loading control. f IHC staining indicating the GOLPH3L protein expression in non-tumor tissues (A); clinical stage I human ovarian cancer (B); clinical stage IV human ovarian cancer (C). g The Kaplan-Meier survival curves compare ovarian cancer patients with low and high GOLPH3L expression levels (n = 177; P < 0.001)